Fort Lee, New Jersey, USA, March 27, 2015 (GLOBE NEWSWIRE) -- Herborium® Group,
Inc. (OTC Pink: HBRM), www.Herborium.com, a Botanical
Therapeutics® Company and the provider of unique all botanical
medicines (Botanical Therapeutics®) announced today that its sales
to HUT Group, LLC. , the UK's leading multi-website online retailer
of Health and Beauty products has doubled over the same period of
2014.
As agreed to in the revised Agreement in December 2014 HUT has
successfully increased its marketing and sales of AcnEase®,
Herborium's unique acne treatment, on its multiple highly
ranked e- commerce platforms, and therefore keept the
sale projection on track for reaching $500,000 sales in Europe
within 18-24 months.
The HUT Group is one of Europe's fastest growing online
lifestyle and health & and beauty destinations. It is
currently the UK's leading multi-website online retailer with
rapidly growing global operations including a significant growth in
Asia. Hut supports more than 140 million global website visitors, 5
million customers and 8 million orders dispatched worldwide across
such on line stores as www.myprotein.com, www.LookFantastic.com,
www.beautyexpert.co.uk,
mankind.co.uk, www.coggles.com and others.
"We are very excited about the present growth in sales of
AcnEase® on HUT's unique "end to end"
technology platform. With potential for a million page views daily
our Botanical Therapeutics® will reach millions of customers in
Europe and Asia. We are expecting HUT goal for $500,000
in sales of AcnEase® to be just a beginning of
Herborium's new growth opportunities in Europe that are also
strongly supported by the continuous growth of our French market
sales. France is the 4th largest world market for beauty
and skincare related products. " commented Dr. Agnes P. Olszewski,
CEO and Chairwoman of Herborium.
About Herborium Group,
Inc.
Herborium Group, Inc., a botanical therapeutics® company that
develops, license and markets proprietary, botanical based
medicinal products to consumers and healthcare professionals. The
Company business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses
clinical validation and a proactive regulatory strategy based on
the FDA Guidance for Industry: Botanical Drug Products
(FDA Guidance 2004) to establish and maintain a
differential advantage. Herborium has secured a pipeline of
botanical ingredients based products in the areas of dermatological
needs, wellness and energy, prostate health, women's health and
selected sexual disorders resulting from cardiovascular disease,
use of anti-depressants, diabetes, surgical procedures, and other
problems. Herborium Group sells its products in the United States,
the United Kingdom, and continental Europe through a network of
distributors, specialty retailers, and e-commerce. For more
information, please visit www.herborium.com, www.acnease.com and
www.acnease.fr.
Safe Harbor Statement: This release contains
forward-looking statements with respect to the results of
operations and business of Herborium Group, Inc., which involves
risks and uncertainties. The Company's actual future results
could materially differ from those discussed. The
Company intends that such statements about the Company's future
expectations, including future revenues and earnings, and all other
forward looking statements be subject to the "Safe Harbors"
provision of the Private Securities Litigation Reform Act of
1995.
CONTACT: Herborium Group, Inc.
Email: InvestorsRelations@Herborium.com